Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin

Drug Development and Industrial Pharmacy

Volumn 32, Issue 6, 2006, Pages 719-726

  Chen, J ^a   Ping, Q N ^a   Guo, J X ^a   Chu, X Z ^a   Song, M M ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

9 Nitrocamptothecin; Hydrogenated soybean phosphatidylcholine; Liposomes; Pharmacokinetics

Indexed keywords

CHOLESTEROL; LIPOSOME; PHOSPHATIDYLCHOLINE; RUBITECAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; MALE; NONHUMAN; RAT; SOYBEAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHOLESTEROL; DRUG COMPOUNDING; FEASIBILITY STUDIES; HYDROGENATION; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOYBEANS;

EID: 33746799255     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500529077     Document Type: Article

References (21)

1. Balasubramanian, S. V., Alderfer, J. L., & Straubinger, R. M. (1994). Solvent- and concentration-dependent molecular interactions of Taxol (Paclitaxel). Journal of Pharmaceutical Science, 83, 1470-1476.
2. Burke, T. G., & Mi, Z. (1994). The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. Journal of Medicinal Chemistry, 37, 40-46.
3. Cao, Z., Harris, N., Kozielski, A., Vardeman, D., Stelin, J. S., & Giovanella, B. (1998). Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity and antitumor activity. Journal of Medicinal Chemistry, 41, 31-37.
4. Chow, D. S., Gong, L., Wolfe, M. D., & Giovanella, B. C. (2000). Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin. Annals NewYork Academy of Sciences, 922, 164-174.
5. Giovanella, B. C., Stehlin, J. S., Hinz, H. R., Kozielski, A. J., Harris, N. J., & Vardeman, D. M. (2002). Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(s)-camptothecin (Rubitecan). International Journal of Oncology, 20, 81-88.
6. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong S. M., Bartus, J. O., Johnson, R. K., & Kingsbury, W. D. (1989). Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. Journal of Medicinal Chemistry, 32, 715-720.
7. Hung, C. L., Doniger, J., Palini, A., Snyder, S. W., Radonovich, M. F., Brady, J. N., Pantazis, P., & Sadaie, M. R. (2001) 9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. Journal of Medical Virology, 64, 238-244.
8. Kan, P., Wang, A. J., Chen, W. K., & Tsa, C. W. (2004). Liposome for incorporating large amounts of hydrophobic substances. US2004126886, July 1, 2004.
9. Konstadoulakis, M. M., Antonakis, P. T., Tsibloulis, B. G., Stathopoulos, G. P., Manouras, A. P., Mylonaki, D. B., & Golematis, B. X. (2001). A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 48, 417-420.
10. Patel, S. R., Beach, J., Papadopoulos, N., Burgess, M. A., Trent, J., & Benjamin, R. S. (2003). Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer, 97, 2848-2852.
11. Punt, C. J., Jonge, M. J., Monfardini, S., Daugaard, G., Fiedler, W., Baron, B., Lacombe, D., & Fumoleau, P. (2004). RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. European Journal of Cancer, 40, 1332-1334.
12. Raymond, E., Campone, M., Stupp, R., Meten, J., Chollet, P., Lesimple, T., Fety-Deporte, R., Lacombe, D., Paoletti, X., & Fumoleau, P. (2002). Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. European Journal of Cancer, 38, 1348-1350.
13. Schoffski, P., Herr, A., Vermorken, J. B., Van den Brande, J., Beijnen, J. H., Rosing, H., Volk, J., Ganser, A., Adank, S., Botma, H. J., & Wanders, J. (2002). Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailiability of the oral camptothecin analogue. European Journal of Cancer, 38, 807-813.
14. Scott, D. O., Bindra, D. S., & Stella, V. J. (1993). Plasma pharmacokinetics of the lactone and carboxylate forms of 20(s)-camptothecin in anesthetized rats. Pharmaceutical Research, 10, 1451-1457.
15. Sha, X., & Fang, X. (2004). Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. International Journal of Pharmaceutics 272, 161-171.
16. Ulukan, H., & Swaan P. W. (2002). Camptothecins: A review of their chemotherapeutic potential. Drugs, 62, 2039-2057.
17. Warner, D. L., & Burke, T. G. (1997). Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. Journal of Chromatography B, 691, 161-171.
18. Yang, S. C., Zhu, J. B., Lu, Y., Liang, B. W., & Yang, C. Z. (1999). Body distribution of camptothecin solid liquid nanoparticles after oral administration. Pharmaceutical Research, 16, 751-757.
19. Yang S. C., & Zhu, J. B. (2002). Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Development and Industrial Pharmacy, 28, 265-274.
20. Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., & Ahmad, I. (2004). Development and characterization of a novel liposome-based formulation of SN-38. International Journal of Pharmaceutics, 270, 93-107.
21. Zhong, D. F., Li, K., Xu, J. H., Du, Y., & Zhang, Y. F. (2003). Pharmacokinetics of 9-nitro-20(s)-camptothecin in rats. Acta Pharmacologica Sinica, 24, 256-262